This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Fragment-Based Drug Discovery

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
== Rasagiline Analogues in Monoamine Oxidase Inhibition ==
+
== Paclitaxel in Apoptosis ==
-
<StructureSection load='2c64' size='350' side='right' caption='Structure of HMG-CoA reductase (PDB entry [[2c64]])' scene=''>
+
<StructureSection load='1ysi' size='350' side='right' caption='Structure of HMG-CoA reductase (PDB entry [[1ysi]])' scene=''>
-
This represents the irreversible and selective inhibition of MAO-B by rasagiline.
+
This represents the inhibition of the anti-apoptotic protein, Bcl-xl, by the anti-cancer drug, paclitaxel.
</StructureSection>
</StructureSection>

Revision as of 19:26, 17 September 2012

Paclitaxel in Apoptosis

Structure of HMG-CoA reductase (PDB entry 1ysi)

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

Justin Weekley, Arthur Cox, Jaime Prilusky

Retrieved from "http://52.214.119.220/wiki/index.php/Fragment-Based_Drug_Discovery"
Personal tools